{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:43:59Z","timestamp":1790066639960,"version":"4.0.1"},"reference-count":98,"publisher":"American Diabetes Association","issue":"6","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,6,1]]},"abstract":"<jats:p>Over the past three decades there have been a number of clinical trials directed at interdicting the type 1 diabetes (T1D) disease process in an attempt to prevent the development of the disease in those at increased risk or to stabilize\u2014potentially even reverse\u2014the disease in people with T1D, usually of recent onset. Unfortunately, to date there has been no prevention trial that has resulted in delay or prevention of T1D. And, trials in people with T1D have had mixed results with some showing promise with at least transient improvement in \u03b2-cell function compared with randomized control groups, while others have failed to slow the decline in \u03b2-cell function when compared with placebo. This Perspective will assess the past and present challenges in this effort and provide an outline for potential future opportunities.<\/jats:p>","DOI":"10.2337\/dc15-0349","type":"journal-article","created":{"date-parts":[[2015,5,21]],"date-time":"2015-05-21T19:25:47Z","timestamp":1432236347000},"page":"997-1007","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":79,"title":["Prevention and Reversal of Type 1 Diabetes\u2014Past Challenges and Future Opportunities"],"prefix":"10.2337","volume":"38","author":[{"given":"Jay S.","family":"Skyler","sequence":"first","affiliation":[{"name":"Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2015,5,12]]},"reference":[{"key":"2022031301280955000_B1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(86)91943-4","article-title":"Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial","volume":"2","author":"Feutren","year":"1986","journal-title":"Lancet"},{"key":"2022031301280955000_B2","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.2337\/diab.37.11.1574","article-title":"Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion","volume":"37","author":"The Canadian-European Randomized Control Trial Group","year":"1988","journal-title":"Diabetes"},{"key":"2022031301280955000_B3","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"346","author":"Herold","year":"2002","journal-title":"N Engl J Med"},{"key":"2022031301280955000_B4","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/diabetes.54.6.1763","article-title":"A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes","volume":"54","author":"Herold","year":"2005","journal-title":"Diabetes"},{"key":"2022031301280955000_B5","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMoa043980","article-title":"Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes","volume":"352","author":"Keymeulen","year":"2005","journal-title":"N Engl J Med"},{"key":"2022031301280955000_B6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00125-009-1644-9","article-title":"Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass","volume":"53","author":"Keymeulen","year":"2010","journal-title":"Diabetologia"},{"key":"2022031301280955000_B7","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N Engl J Med"},{"key":"2022031301280955000_B8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2337\/dc13-0626","article-title":"B-lymphocyte depletion with rituximab and \u03b2-cell function: two-year results","volume":"37","author":"Pescovitz","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031301280955000_B9","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","article-title":"Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"378","author":"Orban","year":"2011","journal-title":"Lancet"},{"key":"2022031301280955000_B10","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2337\/dc13-0604","article-title":"Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment","volume":"37","author":"Orban","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031301280955000_B11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1172\/JCI78492","article-title":"Anti-thymocyte globulin\/G-CSF treatment preserves \u03b2 cell function in patients with established type 1 diabetes","volume":"125","author":"Haller","year":"2015","journal-title":"J Clin Invest"},{"key":"2022031301280955000_B12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(11)60895-7","article-title":"Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial","volume":"378","author":"Wherrett","year":"2011","journal-title":"Lancet"},{"key":"2022031301280955000_B13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1107096","article-title":"GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus","volume":"366","author":"Ludvigsson","year":"2012","journal-title":"N Engl J Med"},{"key":"2022031301280955000_B14","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.2337\/dc13-1391","article-title":"DIA-AID 1 Writing Group. Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial [retracted in: Diabetes Care 2015;38:178]","volume":"37","author":"Raz","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031301280955000_B15","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.2337\/dc13-1392","article-title":"Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal [retracted in: Diabetes Care 2015;38:179]","volume":"37","author":"Pozzilli","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031301280955000_B16","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2337\/dc09-1349","article-title":"Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes","volume":"33","author":"Gottlieb","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031301280955000_B17","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(13)60023-9","article-title":"Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials","volume":"381","author":"Moran","year":"2013","journal-title":"Lancet"},{"key":"2022031301280955000_B18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-8587(13)70065-2","article-title":"Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: a randomized double-blind phase 2 trial","volume":"1","author":"Gitelman","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031301280955000_B19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(13)70111-6","article-title":"Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial","volume":"1","author":"Rigby","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031301280955000_B20","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.2337\/diacare.28.5.1068","article-title":"Diabetes Prevention Trial\u2013Type 1 Diabetes Study Group. Effects of oral insulin in relatives of patients with type 1 diabetes mellitus","volume":"28","author":"Skyler","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031301280955000_B21","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa012350","article-title":"Effects of insulin in relatives of patients with type 1 diabetes mellitus","volume":"346","author":"Diabetes Prevention Trial\u2013Type 1 Diabetes Study Group","year":"2002","journal-title":"N Engl J Med"},{"key":"2022031301280955000_B22","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/0140-6736(93)91215-8","article-title":"Insulin prophylaxis in individuals at high risk of type I diabetes","volume":"341","author":"Keller","year":"1993","journal-title":"Lancet"},{"key":"2022031301280955000_B23","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s001250050943","article-title":"Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial","volume":"41","author":"F\u00fcchtenbusch","year":"1998","journal-title":"Diabetologia"},{"key":"2022031301280955000_B24","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa0804328","article-title":"GAD treatment and insulin secretion in recent-onset type 1 diabetes","volume":"359","author":"Ludvigsson","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031301280955000_B25","unstructured":"Diamyd initiates closure of US phase III study [press release]. Stockholm, Sweden: Diamyd Medical AB; June 23, 2011. Available from http:\/\/www.diamyd.com\/docs\/pressClip.aspx?section=investor&ClipID=58443. Accessed 15 February 2015"},{"key":"2022031301280955000_B26","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(01)06801-5","article-title":"\u03b2-Cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial","volume":"358","author":"Raz","year":"2001","journal-title":"Lancet"},{"key":"2022031301280955000_B27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/dmrr.712","article-title":"Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial","volume":"23","author":"Raz","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031301280955000_B28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/dmrr.711","article-title":"Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study","volume":"23","author":"Lazar","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031301280955000_B29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/dmrr.691","article-title":"Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients","volume":"23","author":"Huurman","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031301280955000_B30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/dmrr.707","article-title":"Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials","volume":"23","author":"Schloot","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031301280955000_B31","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc13-2878","article-title":"Struggles with clinical translation of immune intervention trials","volume":"37","author":"Skyler","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031301280955000_B32","doi-asserted-by":"crossref","first-page":"e41756","DOI":"10.1371\/journal.pone.0041756","article-title":"Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes","volume":"7","author":"Faustman","year":"2012","journal-title":"PLoS One"},{"key":"2022031301280955000_B33","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2337\/diacare.21.10.1691","article-title":"Effect of bacille Calmette-Gu\u00e9rin vaccination on C-peptide secretion in children newly diagnosed with IDDM","volume":"21","author":"Elliott","year":"1998","journal-title":"Diabetes Care"},{"key":"2022031301280955000_B34","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.2337\/diacare.22.10.1703","article-title":"Effect of Bacillus Calmette-Gu\u00e9rin vaccination on new-onset type 1 diabetes. A randomized clinical study","volume":"22","author":"Allen","year":"1999","journal-title":"Diabetes Care"},{"key":"2022031301280955000_B35","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(11)60931-8","article-title":"Teplizumab for treatment of type 1 diabetes (Prot\u00e9g\u00e9 study): 1-year results from a randomised, placebo-controlled trial","volume":"378","author":"Sherry","year":"2011","journal-title":"Lancet"},{"key":"2022031301280955000_B36","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.2337\/db13-0236","article-title":"Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Prot\u00e9g\u00e9 trial","volume":"62","author":"Hagopian","year":"2013","journal-title":"Diabetes"},{"key":"2022031301280955000_B37","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.2337\/dc13-0327","article-title":"Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes","volume":"37","author":"Aronson","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031301280955000_B38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/dme.12361","article-title":"Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study","volume":"31","author":"Ambery","year":"2014","journal-title":"Diabet Med"},{"key":"2022031301280955000_B39","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/blood-2009-02-204875","article-title":"Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients","volume":"115","author":"Keymeulen","year":"2010","journal-title":"Blood"},{"key":"2022031301280955000_B40","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2217\/imt.11.123","article-title":"Otelixizumab in the treatment of type 1 diabetes mellitus","volume":"3","author":"Sprangers","year":"2011","journal-title":"Immunotherapy"},{"key":"2022031301280955000_B41","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.2337\/db14-1322","article-title":"Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes","volume":"64","author":"Yu","year":"2015","journal-title":"Diabetes"},{"key":"2022031301280955000_B42","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMe1110900","article-title":"The yin and yang of interleukin-2-mediated immunotherapy","volume":"365","author":"Bluestone","year":"2011","journal-title":"N Engl J Med"},{"key":"2022031301280955000_B43","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N Engl J Med"},{"key":"2022031301280955000_B44","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N Engl J Med"},{"key":"2022031301280955000_B45","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.2337\/db12-0049","article-title":"Rapamycin\/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs \u03b2-cell function","volume":"61","author":"Long","year":"2012","journal-title":"Diabetes"},{"key":"2022031301280955000_B46","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031301280955000_B47","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.2337\/db08-0688","article-title":"Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice","volume":"57","author":"Suarez-Pinzon","year":"2008","journal-title":"Diabetes"},{"key":"2022031301280955000_B48","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S2213-8587(14)70115-9","article-title":"Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial","volume":"2","author":"Griffin","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031301280955000_B49","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev.immunol.23.021704.115643","article-title":"The NOD mouse: a model of immune dysregulation","volume":"23","author":"Anderson","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"2022031301280955000_B50","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.immuni.2005.08.002","article-title":"A comprehensive review of interventions in the NOD mouse and implications for translation","volume":"23","author":"Shoda","year":"2005","journal-title":"Immunity"},{"key":"2022031301280955000_B51","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.diabet.2009.02.005","article-title":"Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients","volume":"35","author":"Vandemeulebroucke","year":"2009","journal-title":"Diabetes Metab"},{"key":"2022031301280955000_B52","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/S0140-6736(08)61309-4","article-title":"Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial","volume":"372","author":"N\u00e4nt\u00f6-Salonen","year":"2008","journal-title":"Lancet"},{"key":"2022031301280955000_B53","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(00)02579-4","article-title":"Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diab\u00e8te Insuline Orale group","volume":"356","author":"Chaillous","year":"2000","journal-title":"Lancet"},{"key":"2022031301280955000_B54","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1007\/s001250051482","article-title":"No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII)","volume":"43","author":"Pozzilli","year":"2000","journal-title":"Diabetologia"},{"key":"2022031301280955000_B55","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1196\/annals.1309.057","article-title":"Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes","volume":"1029","author":"Ergun-Longmire","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"2022031301280955000_B56","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/dc09-0449","article-title":"No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes","volume":"32","author":"Walter","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031301280955000_B57"},{"key":"2022031301280955000_B58","unstructured":"Lund University. Diabetes Prevention \u2013Immune Tolerance (DIAPREV-IT). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2010. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01122446 NLM Identifier: NCT01122446. Accessed 15 February 2015"},{"key":"2022031301280955000_B59","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Oral insulin for prevention of diabetes in relatives at risk for type 1 diabetes mellitus. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2007. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00419562 NLM Identifier: NCT00419562. Accessed 15 February 2015"},{"key":"2022031301280955000_B60","unstructured":"Melbourne Health. Trial of intranasal insulin in children and young adults at risk of type 1 diabetes (INIT II). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2006. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00336674 NLM Identifier: NCT00336674. Accessed 15 February 2015"},{"key":"2022031301280955000_B61","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2249.2008.03814.x","article-title":"Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man phase I safety study","volume":"155","author":"Thrower","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"2022031301280955000_B62","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.2337\/db13-0345","article-title":"Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders","volume":"62","author":"Herold","year":"2013","journal-title":"Diabetes"},{"key":"2022031301280955000_B63","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.2337\/db14-0095","article-title":"Recommendations for the definition of clinical responder in insulin preservation studies","volume":"63","author":"Beam","year":"2014","journal-title":"Diabetes"},{"key":"2022031301280955000_B64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/db10-1114","article-title":"Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man","volume":"60","author":"Skyler","year":"2011","journal-title":"Diabetes"},{"key":"2022031301280955000_B65","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.2337\/db14-0365","article-title":"Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes","volume":"63","author":"Arif","year":"2014","journal-title":"Diabetes"},{"key":"2022031301280955000_B66","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1056\/NEJMoa1004809","article-title":"Dietary intervention in infancy and later signs of beta-cell autoimmunity","volume":"363","author":"Knip","year":"2010","journal-title":"N Engl J Med"},{"key":"2022031301280955000_B67","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1001\/jama.2014.5610","article-title":"Hydrolyzed infant formula and early \u03b2-cell autoimmunity: a randomized clinical trial","volume":"311","author":"Knip","year":"2014","journal-title":"JAMA"},{"key":"2022031301280955000_B68","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1001\/archpediatrics.2011.1559","article-title":"Removal of bovine insulin from cow's milk formula and early initiation of beta-cell autoimmunity in the FINDIA pilot study","volume":"166","author":"Vaarala","year":"2012","journal-title":"Arch Pediatr Adolesc Med"},{"key":"2022031301280955000_B69","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2337\/dc10-2456","article-title":"Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study","volume":"34","author":"Hummel","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031301280955000_B70","doi-asserted-by":"crossref","first-page":"980","DOI":"10.2337\/diabetes.47.6.980","article-title":"The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes","volume":"47","author":"Lampeter","year":"1998","journal-title":"Diabetes"},{"key":"2022031301280955000_B71","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0140-6736(04)15786-3","article-title":"European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes","volume":"363","author":"Gale","year":"2004","journal-title":"Lancet"},{"key":"2022031301280955000_B72","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Teplizumab for prevention of type 1 diabetes in relatives \u201cat-risk.\u201d In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2009. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01030861 NLM Identifier: NCT01030861. Accessed 15 February 2015"},{"key":"2022031301280955000_B73","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. CTLA4-Ig (abatacept) for prevention of abnormal glucose tolerance and diabetes in relatives at-risk for type 1 diabetes mellitus. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2010. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01773707 NLM Identifier: NCT01773707. Accessed 15 February 2015"},{"key":"2022031301280955000_B74","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM198809083191002","article-title":"Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus","volume":"319","author":"Silverstein","year":"1988","journal-title":"N Engl J Med"},{"key":"2022031301280955000_B75","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.2337\/diab.34.12.1306","article-title":"Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine","volume":"34","author":"Harrison","year":"1985","journal-title":"Diabetes"},{"key":"2022031301280955000_B76","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2337\/diab.38.6.779","article-title":"Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes","volume":"38","author":"Cook","year":"1989","journal-title":"Diabetes"},{"key":"2022031301280955000_B77","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s001250051028","article-title":"Low dose linomide in type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial","volume":"41","author":"Coutant","year":"1998","journal-title":"Diabetologia"},{"key":"2022031301280955000_B78","unstructured":"MacroGenics. Protege Encore study\u2013clinical trial of teplizumab (MGA031) in children and adults with recent-onset type 1 diabetes mellitus. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2009. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00920582 NLM Identifier: NCT00920582. Accessed 15 February 2015"},{"key":"2022031301280955000_B79","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00125-012-2753-4","article-title":"Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial","volume":"56","author":"Herold","year":"2013","journal-title":"Diabetologia"},{"key":"2022031301280955000_B80","doi-asserted-by":"crossref","first-page":"E1418","DOI":"10.1210\/jc.2013-3864","article-title":"\u03b11-Antitrypsin therapy downregulates Toll-like receptor-induced IL-1\u03b2 responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes","volume":"99","author":"Gottlieb","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031301280955000_B81","doi-asserted-by":"crossref","first-page":"e17554","DOI":"10.1371\/journal.pone.0017554","article-title":"Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial","volume":"6","author":"Martin","year":"2011","journal-title":"PLoS One"},{"key":"2022031301280955000_B82","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2337\/dc09-0054","article-title":"Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study","volume":"32","author":"Mastrandrea","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031301280955000_B83","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.297.14.1568","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus","volume":"297","author":"Voltarelli","year":"2007","journal-title":"JAMA"},{"key":"2022031301280955000_B84","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.2009.470","article-title":"C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus","volume":"301","author":"Couri","year":"2009","journal-title":"JAMA"},{"key":"2022031301280955000_B85","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/jama.2009.1100","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus","volume":"302","author":"Voltarelli","year":"2009","journal-title":"JAMA"},{"key":"2022031301280955000_B86","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.2337\/db14-0295","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis","volume":"63","author":"D\u2019Addio","year":"2014","journal-title":"Diabetes"},{"key":"2022031301280955000_B87","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. ATG-GCSF in new onset type 1 diabetes. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2014. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02215200 NLM Identifier: NCT02215200. Accessed 15 February 2015"},{"key":"2022031301280955000_B88","unstructured":"National Institute of Allergy and Infectious Diseases. TCZ in new-onset type 1 diabetes. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2014. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02293837 NLM Identifier: NCT02293837. Accessed 15 February 2015"},{"key":"2022031301280955000_B89","unstructured":"GlaxoSmithKline. Investigation of otelixizumab in new-onset, autoimmune type 1 diabetes mellitus patients. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2013. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02000817 NLM Identifier: NCT02000817. Accessed 15 February 2015"},{"key":"2022031301280955000_B90","unstructured":"Kamada, Ltd. Phase II-III study to evaluate the efficacy and safety of alpha-1-anti-trypsin (Glassia) in type-1 diabetes. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2013. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02005848 NLM Identifier: NCT02005848. Accessed 15 February 2015"},{"key":"2022031301280955000_B91","unstructured":"Grifols Therapeutics Inc. Study of human plasma-derived alpha1-proteinase inhibitor in subjects with new-onset type 1 diabetes mellitus. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2014. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02093221 NLM Identifier: NCT02093221. Accessed 15 February 2015"},{"key":"2022031301280955000_B92","unstructured":"University of British Columbia. Pilot clinical trial of ustekinumab in patients with new-onset T1D. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2014. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02117765 NLM Identifier: NCT02117765. Accessed 15 February 2015"},{"key":"2022031301280955000_B93","unstructured":"University of California, San Francisco. Imatinib treatment in recent onset type 1 diabetes mellitus. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2013. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01781975 NLM Identifier: NCT01781975 Accessed 15 February 2015"},{"key":"2022031301280955000_B94","unstructured":"Goland, R. Tauroursodeoxycholic acid (TUDCA) in new-onset type 1 diabetes. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2014. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02218619 NLM Identifier: NCT02218619. Accessed 15 February 2015"},{"key":"2022031301280955000_B95","unstructured":"Ludvigsson, J. DIABGAD\u2014trial to preserve insulin secretion in type 1 diabetes using GAD-alum (Diamyd) in combination with vitamin d and ibuprofen. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2013. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01785108 NLM Identifier: NCT01785108. Accessed 15 February 2015"},{"key":"2022031301280955000_B96","unstructured":"Cardiff University. Safety study to assess whether proinsulin peptide injections can slow or stop the body damaging its own insulin-making cells in the pancreas in patients newly diagnosed with type 1 diabetes (MonoPepT1De). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2012. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01536431 NLM Identifier: NCT01536431. Accessed 15 February 2015"},{"key":"2022031301280955000_B97","unstructured":"University of Colorado Denver School of Medicine Barbara Davis Center. Effect of methyldopa on MHC class II antigen presentation in type 1 diabetes. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2013. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01883804 NLM Identifier: NCT01883804. Accessed 15 February 2015"},{"key":"2022031301280955000_B98","unstructured":"Assistance Publique-H\u00f4pitaux de Paris. dose finding study of Il-2 at ultra-low dose in children with recently diagnosed type 1 diabetes (DFIL2-Child). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2012. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01862120 NLM Identifier: NCT01862120. Accessed 15 February 2015"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/38\/6\/997\/625275\/dc150349.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/38\/6\/997\/625275\/dc150349.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T05:19:31Z","timestamp":1647148771000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/38\/6\/997\/37387\/Prevention-and-Reversal-of-Type-1-Diabetes-Past"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,12]]},"references-count":98,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,5,12]]},"published-print":{"date-parts":[[2015,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc15-0349","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,12]]}}}